Anand Sofinnova Venture Par... Net Worth

The estimated Net Worth of Anand Sofinnova Venture Par... is at least $1.06 Миллион dollars as of 20 October 2016. Anand Par owns over 750,683 units of Marinus Pharmaceuticals Inc stock worth over $21,503 and over the last 10 years Anand sold MRNS stock worth over $1,043,449.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Anand Par MRNS stock SEC Form 4 insiders trading

Anand has made over 2 trades of the Marinus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Anand sold 750,683 units of MRNS stock worth $1,043,449 on 20 October 2016.

The largest trade Anand's ever made was selling 750,683 units of Marinus Pharmaceuticals Inc stock on 20 October 2016 worth over $1,043,449. On average, Anand trades about 750,683 units every 404 days since 2014. As of 20 October 2016 Anand still owns at least 15,470 units of Marinus Pharmaceuticals Inc stock.

You can see the complete history of Anand Par stock trades at the bottom of the page.

Insiders trading at Marinus Pharmaceuticals Inc

Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... и Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.

What does Marinus Pharmaceuticals Inc do?

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides

Complete history of Anand Par stock trades at Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc executives and stock owners

Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Scott Braunstein,
  President, Chief Executive Officer, Director
• Edward Smith,
  Chief Financial Officer
• Dr. Scott N. Braunstein M.D.,
  CEO, Pres & Director
• Dr. Scott Braunstein,
  CEO, Pres & Director
• Edward F. Smith CPA,
  Consultant
• Dr. Joseph Hulihan M.D.,
  Chief Medical Officer
• Joseph Hulihan,
  Chief Medical Officer
• Timothy Mayleben,
  Independent Director
• Nicole Vitullo,
  Chairman of the Board
• Michael Dougherty,
  Independent Director
• Seth Fischer,
  Independent Director
• Enrique Carrazana,
  Independent Director
• Elan Ezickson,
  Independent Director
• Charles Austin,
  Director
• Sasha Damouni Ellis,
  Vice President of Investor Relations
• Martha Manning,
  Vice President, General Counsel, Secretary
• Dr. Kimberly A. McCormick Pharm.D., PharmD,
  Sr. VP of Regulatory Affairs
• Sonya Weigle,
  VP of HR
• Lisa Lejuwaan,
  VP of Sales
• Steven E. Pfanstiel C.M.A., M.B.A.,
  CFO & Treasurer
• Dr. Kimberly A. McCormick,
  VP of Regulatory Affairs
• Christy Shafer,
  Chief Commercial Officer
• Dr. Alex Aimetti,
  Head of Scientific Affairs
• Rose McKinley,
  VP of HR & Organizational Devel.
• Thomas J. Lyons,
  VP of Corp., Bus. Devel. & Commercial Planning
• Martha E. Manning,
  VP, Gen. Counsel & Sec.
• Stephen M Bloch,
  Director
• Christopher Michael Cashman,
  PRESIDENT AND CEO
• Jay Shepard,
  Director
• Anand Sofinnova Venture Par...,
  
• Anand Mehra,
  Director
• Gail M Farfel,
  Chief Clinical Dev & Reg
• Vii L P Canaan Partners Vii...,
  
• Albena Patroneva,
  Chief Medical Officer
• Masuoka K. Lorianne,
  Chief Medical Officer
• Capital Life Sciences Inves...,
  
• Christine Berni Silverstein,
  
• Sara Nochur,
  
• Anton Gopka,
  Director
• Partners Vi, L.P.Blair Jame...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Marvin Johnson,
  
• Santiago Arroyo,
  Director
• Sarah B. Noonberg,
  
• Christina Shafer,
  CHIEF COMMERCIAL OFFICER
• Steven Pfanstiel,
  CFO AND COO